Why Halozyme Therapeutics Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Halozyme Therapeutics (NASDAQ: HALO  ) , a biopharmaceutical company focused on the development of human enzymes, jumped as much as 19% after the company announced its plans to present clinical data on its phase 1b trial for PEPGPH20 at the American Society of Clinical Oncology meeting later this month.

So what: PEPGPH20 is currently being tested in combination with Eli Lilly's Gemzar to treat metastatic pancreatic cancer. Based on the results from Halozyme's 28 patient phase 1b trial, the overall response rate was 42%, and the treatment appeared to be well tolerated by patients. In April, Halozyme initiated a phase 2 124-patient trial as a first-line treatment for metastatic pancreatic cancer.

Now what: Much like we've witnessed over the past week, investors are getting pretty excited about ASCO -- essentially the most important conference all year for cancer-focused biotechnology companies. While the initial data for Halozyme's investigational new biologic treatment is encouraging, I feel it's still far too early in the process for a double-digit move like the one we're seeing today. Halozyme is a company worth adding to your watchlist, but it's not a particularly intriguing buy candidate as of yet.

Craving more input? Start by adding Halozyme Therapeutics to your free and personalized watchlist so you can keep up on the latest news with the company. 

While you can certainly make huge gains in biotechs like Halozyme Therapeutics, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2436127, ~/Articles/ArticleHandler.aspx, 12/18/2014 10:57:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement